The Société Tunisienne des Industries Pharmaceutiques (SIPHAT) has announced the resumption of most of its production units, with particular emphasis on the production unit for intravenous solutions in bags.
SIPHAT has several production units, including one for intravenous solutions in vials, one for dry forms (medicines and tablets) and one for pasty forms (ointments).
The company has also relaunched the production of medicines and medical devices that can be manufactured locally, applying strict production, storage and distribution control standards to ensure high quality.
SIPHAT has announced the reallocation of human resources according to production needs and the doubling of production to meet the needs of the national market.
It has also digitalized production and distribution channels to improve the efficiency of the management of medicines and medical supplies.
